Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04152863
Registration number
NCT04152863
Ethics application status
Date submitted
4/11/2019
Date registered
5/11/2019
Date last updated
4/03/2024
Titles & IDs
Public title
Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)
Query!
Scientific title
A Phase 2, Randomized Clinical Study of Intravenous or Intratumoral Administration of V937 in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma
Query!
Secondary ID [1]
0
0
2019-002034-36
Query!
Secondary ID [2]
0
0
V937-011
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Advanced/Metastatic Melanoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Malignant melanoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - Gebasaxturev IV
Other interventions - Gebasaxturev ITu
Treatment: Drugs - Pembrolizumab
Experimental: IV Gebasaxturev + Pembrolizumab - Participants receive gebasaxturev at a dose of 1 X 10^9 TCID50 by IV infusion on Days 1, 3, 5, and 8 of Cycle 1 (28-day cycle) and Day 1 of Cycles 2-8 (21-day cycles) plus pembrolizumab 200 mg by IV infusion on Day 8 of Cycle 1 (28-day cycle) and Day 1 of each subsequent 21-day cycle. Gebasaxturev will be administered for up to 8 cycles (up to 6 months). Pembrolizumab will be administered for up to 35 cycles (up to 2 years).
Experimental: ITu Gebasaxturev + Pembrolizumab - Participants receive gebasaxturev at a dose of 3 X 10^8 TCID50 by ITu injection on Days 1, 3, 5, and 8 of Cycle 1 (28-day cycle) and Day 1 of Cycles 2-8 (21-day cycles) plus pembrolizumab 200 mg by IV infusion on Day 8 of Cycle 1 (28-day cycle) and Day 1 of each subsequent 21-day cycle. Gebasaxturev will be administered for up to 8 cycles (up to 6 months). Pembrolizumab will be administered for up to 35 cycles (up to 2 years).
Experimental: Pembrolizumab - Participants receive pembrolizumab 200 mg by IV infusion on Day 8 of Cycle 1 (28-day cycle) and Day 1 of each subsequent 21-day cycle. Pembrolizumab will be administered for up to 35 cycles (up to 2 years).
Other interventions: Gebasaxturev IV
Administered as an IV infusion of 1 X 10^9 TCID50
Other interventions: Gebasaxturev ITu
Administered as an ITu injection of 3 X 10^8 TCID50
Treatment: Drugs: Pembrolizumab
Administered as an IV infusion of 200 mg
Query!
Intervention code [1]
0
0
Other interventions
Query!
Intervention code [2]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Objective Response Rate (ORR) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
Query!
Assessment method [1]
0
0
ORR is defined as the percentage of participants who have a Complete Response (CR: disappearance of all lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions, without evidence of progression based on non-target or new lesions) as assessed by BICR per RECIST 1.1 which is modified for this study to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. The percentage of participants who experience a CR or PR based on modified RECIST 1.1 will be presented.
Query!
Timepoint [1]
0
0
Up to 3 years
Query!
Secondary outcome [1]
0
0
Progression-free Survival (PFS) per RECIST 1.1 as Assessed by BICR
Query!
Assessment method [1]
0
0
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as either a 20% increase from nadir in target lesions, unequivocal progression of non-target lesions, or the appearance of new lesions. PFS will be assessed by BICR for this outcome measure.
Query!
Timepoint [1]
0
0
Up to 3 years
Query!
Secondary outcome [2]
0
0
Duration of Response (DOR) per RECIST 1.1 as Assessed by BICR
Query!
Assessment method [2]
0
0
For participants who demonstrate a confirmed complete response (CR: disappearance of all lesions) or confirmed Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions, without evidence of progression based on non-target or new lesions.) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first. RECIST 1.1 has been modified for this study to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, and will be assessed by BICR for this outcome measure.
Query!
Timepoint [2]
0
0
Up to 3 years
Query!
Secondary outcome [3]
0
0
ORR per RECIST 1.1 as Assessed by the Investigator
Query!
Assessment method [3]
0
0
ORR is defined as the percentage of participants who have a confirmed Complete Response (CR: disappearance of all lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters [SOD] of target lesions, without evidence of progression based on non-target or new lesions.) as assessed by the investigator per RECIST 1.1, which is modified for this study to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. The percentage of participants who experience a CR or PR based on modified RECIST 1.1 will be presented.
Query!
Timepoint [3]
0
0
Up to 3 years
Query!
Secondary outcome [4]
0
0
PFS per RECIST 1.1 as Assessed by the Investigator
Query!
Assessment method [4]
0
0
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as either a 20% increase from nadir in target lesions, unequivocal progression of non-target lesions, or the appearance of new lesions. PFS will be assessed by the investigator for this outcome measure.
Query!
Timepoint [4]
0
0
Up to 3 years
Query!
Secondary outcome [5]
0
0
DOR per RECIST 1.1 as Assessed by the Investigator
Query!
Assessment method [5]
0
0
For participants who demonstrate a confirmed complete response (CR: disappearance of all lesions) or confirmed Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death. DOR will be assessed by the investigator for this outcome measure.
Query!
Timepoint [5]
0
0
Up to 3 years
Query!
Secondary outcome [6]
0
0
Overall Survival (OS)
Query!
Assessment method [6]
0
0
OS is defined as the time from the date of study treatment to the date of death due to any cause.
Query!
Timepoint [6]
0
0
Up to 3 years
Query!
Secondary outcome [7]
0
0
Number of Participants with One or More Adverse Events (AEs)
Query!
Assessment method [7]
0
0
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experience at least one AE will be reported.
Query!
Timepoint [7]
0
0
Up to 30 days after last dose (up to 3 years)
Query!
Secondary outcome [8]
0
0
Number of Participants who Discontinue Study Drug Due to an AE
Query!
Assessment method [8]
0
0
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who discontinue study treatment due to an AE will be reported.
Query!
Timepoint [8]
0
0
Up to 2 years
Query!
Eligibility
Key inclusion criteria
- Has histologically or cytologically confirmed diagnosis of advanced/metastatic
melanoma.
- Has Stage III or Stage IV melanoma.
- Must be naive to anti-PD-L1 treatment, talimogene laherparepvec (TVEC) and other
oncolytic viruses.
- Has 2 lesions as defined below:
- At least 1 cutaneous or subcutaneous lesion that is amenable to IT injection and
biopsy and measurable per RECIST 1.1
- At least 1 distant and/or discrete noninjected lesion that is amenable to biopsy
and measurable per RECIST 1.1
- Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)
Performance Scale
- Demonstrates adequate organ function
- Male participants refrain from donating sperm during the intervention period and for
at least 120 days after the last dose of study intervention PLUS are either abstinent
from heterosexual intercourse OR agree to use approved contraception during that
period
- Female participants are not pregnant or breastfeeding and are not a woman of
childbearing potential (WOCBP) OR are a WOCBP that agrees to use contraception during
the treatment and for at least 120 days after the last dose of study intervention
- Has measurable disease per RECIST 1.1
- Is able to provide newly obtained core or excisional biopsy of a tumor lesion not
previously irradiated
- Human Immunodeficiency Virus (HIV)-infected participants must have well controlled HIV
on anti-retroviral therapy (ART), defined as:
- Must have Cluster of Differentiation 4 (CD4)+ T-cell count >350 cells/mm^3 at
time of screening
- Must have achieved and maintained virologic suppression
- Must have been on a stable regimen, without changes in drugs or dose
modification, for at least 4 weeks prior to study entry
- The combination ART regimen must not contain any antiretroviral medication other
than abacavir, dolutegravir, emtricitabine, lamivudine, raltegravir, rilpivirine,
or tenofovir
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Has had chemotherapy, definitive radiation, or biological cancer therapy or an
investigational agent or investigational device within 4 weeks prior to the first dose
of study intervention or has not recovered to Common Terminology Criteria for Adverse
Events (CTCAE) Grade 1 or better from any AEs that were due to cancer therapeutics
administered more than 4 weeks earlier
- Has ocular melanoma
- Has radiographic evidence of major blood vessel infiltration
- Has clinically significant hemoptysis or tumor bleeding within 2 weeks prior to the
first dose of study drug
- Has an active autoimmune disease that has required systemic treatment in the past 2
years except vitiligo or resolved childhood asthma/atopy
- HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric
Castleman's Disease
- Has a known psychiatric or substance abuse disorder that would interfere with the
participant's ability to cooperate with the study requirements
- Has undergone allogeneic hematopoietic stem cell transplantation within the last 5
years
- Has not fully recovered from major surgery without significant detectable infection
- Active cardiovascular disease (<6 months prior to enrollment), myocardial infarction
(<6 months prior to enrollment), unstable angina, congestive heart failure or serious
cardiac arrhythmia requiring medication
- Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or other
agents such as cytotoxic T-lymphocyte-associated protein-4 (CTLA-4), OX-40, Cluster of
Differentiation 137 (CD137)
- Has received a live vaccine within 30 days prior to the first dose of study drug
- Is currently participating in or has participated in a study of an investigational
agent or has used an investigational device within 4 weeks prior to the first dose of
study intervention
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
in excess of replacement doses or any other form of immunosuppressive therapy within 7
days prior the first dose of study drug
- Has a known additional malignancy that is progressing or has required active treatment
within the past 2 years
- Has known active central nervous system (CNS) metastases and/or carcinomatous
meningitis
- Has hypersensitivity to pembrolizumab and/or any of its excipients
- Has hypersensitivity to gebasaxturev or any of its excipients
- Has a history of (non-infectious) pneumonitis that required steroids or has current
pneumonitis
- Has an active infection requiring systemic therapy
- Has a known history of Hepatitis B or known active Hepatitis C virus infection
- Has a history or current evidence of any condition, therapy, or laboratory abnormality
that might confound the results of the study, interfere with the participant's
participation for the full duration of the study, or is not in the best interest of
the participant to participate, in the opinion of the treating investigator
- Has had an allogenic tissue/solid organ transplant
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
5/06/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
12/07/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
85
Query!
Recruitment in Australia
Recruitment state(s)
SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
The Queen Elizabeth Hospital ( Site 0143) - Woodville
Query!
Recruitment hospital [2]
0
0
Alfred Health ( Site 0142) - Melbourne
Query!
Recruitment hospital [3]
0
0
Fiona Stanley Hospital ( Site 0141) - Murdoch
Query!
Recruitment postcode(s) [1]
0
0
5011 - Woodville
Query!
Recruitment postcode(s) [2]
0
0
3004 - Melbourne
Query!
Recruitment postcode(s) [3]
0
0
6150 - Murdoch
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Michigan
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
New Jersey
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Oregon
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Washington
Query!
Country [5]
0
0
Chile
Query!
State/province [5]
0
0
Region M. De Santiago
Query!
Country [6]
0
0
France
Query!
State/province [6]
0
0
Cote-d Or
Query!
Country [7]
0
0
France
Query!
State/province [7]
0
0
Isere
Query!
Country [8]
0
0
Germany
Query!
State/province [8]
0
0
Baden-Wurttemberg
Query!
Country [9]
0
0
Germany
Query!
State/province [9]
0
0
Bayern
Query!
Country [10]
0
0
Germany
Query!
State/province [10]
0
0
Sachsen
Query!
Country [11]
0
0
Israel
Query!
State/province [11]
0
0
Haifa
Query!
Country [12]
0
0
Israel
Query!
State/province [12]
0
0
Jerusalem
Query!
Country [13]
0
0
Israel
Query!
State/province [13]
0
0
Ramat Gan
Query!
Country [14]
0
0
Italy
Query!
State/province [14]
0
0
Milano
Query!
Country [15]
0
0
Italy
Query!
State/province [15]
0
0
Siena
Query!
Country [16]
0
0
Korea, Republic of
Query!
State/province [16]
0
0
Seoul
Query!
Country [17]
0
0
Norway
Query!
State/province [17]
0
0
Oslo
Query!
Country [18]
0
0
South Africa
Query!
State/province [18]
0
0
Gauteng
Query!
Country [19]
0
0
South Africa
Query!
State/province [19]
0
0
Western Cape
Query!
Country [20]
0
0
Spain
Query!
State/province [20]
0
0
Gipuzkoa
Query!
Country [21]
0
0
Spain
Query!
State/province [21]
0
0
Navarra
Query!
Country [22]
0
0
Spain
Query!
State/province [22]
0
0
Valenciana, Comunitat
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Merck Sharp & Dohme LLC
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a Phase 2 study to assess the efficacy, safety, and tolerability of gebasaxturev
administered both intratumorally (ITu) and intravenously (IV) as combination therapy with
pembrolizumab (MK-3475) versus pembrolizumab alone in anti-programmed cell death ligand 1
(anti-PD-L1)-treatment-naive participants with advanced/metastatic melanoma. The primary
hypothesis of the study is that gebasaxturev administered either ITu or IV in combination
with pembrolizumab results in a superior objective response rate (ORR) per Response
Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) based on blinded independent
central review (BICR), compared to pembrolizumab alone. This study will be terminated once
all participants finish treatment with V937. Participants eligible to continue to receive
pembrolizumab will be transferred to MK-3475-587 study.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04152863
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Director
Query!
Address
0
0
Merck Sharp & Dohme LLC
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04152863
Download to PDF